Atopic dermatitis is a chronic,relapsing,non-contiguous,exudative eczema/dermatitis,which represents a complex,multi-factorial disorder,due to an impairment of the stratum corneum barrier.Currently available drugs hav...Atopic dermatitis is a chronic,relapsing,non-contiguous,exudative eczema/dermatitis,which represents a complex,multi-factorial disorder,due to an impairment of the stratum corneum barrier.Currently available drugs have a low skin bioavailability and may give rise to severe adverse events.Nanotechnologies,including nanoparticles,liposomes,nano-gels,nano-mixtures,nano-emulsions and other nano-carriers,offer unprecedented solutions to these issues,enabling:i)the management of different clinical forms of atopic dermatitis,especially the recalcitrant ones,i)a better bio-availability and trans-dermal drug targeted delivery at the inflammation site,ii)dose control,iii)significant improvements both in clinical symptoms and immune responses,iv)with less adverse events being reported and a better safety profile.However,some nano-sized structures could amplify and even worsen symptoms in particularly susceptible individuals.Furthermore,most studies included in the present systematic review have been conducted in-vitro or in-vivo,with few randomized controlled clinical trials(RCTs).Future investigations should adopt this design in order to enable scholars achieving robust findings and evidence.Therefore,given the above-mentioned shortcomings,further research in the field is urgently warranted.展开更多
文摘Atopic dermatitis is a chronic,relapsing,non-contiguous,exudative eczema/dermatitis,which represents a complex,multi-factorial disorder,due to an impairment of the stratum corneum barrier.Currently available drugs have a low skin bioavailability and may give rise to severe adverse events.Nanotechnologies,including nanoparticles,liposomes,nano-gels,nano-mixtures,nano-emulsions and other nano-carriers,offer unprecedented solutions to these issues,enabling:i)the management of different clinical forms of atopic dermatitis,especially the recalcitrant ones,i)a better bio-availability and trans-dermal drug targeted delivery at the inflammation site,ii)dose control,iii)significant improvements both in clinical symptoms and immune responses,iv)with less adverse events being reported and a better safety profile.However,some nano-sized structures could amplify and even worsen symptoms in particularly susceptible individuals.Furthermore,most studies included in the present systematic review have been conducted in-vitro or in-vivo,with few randomized controlled clinical trials(RCTs).Future investigations should adopt this design in order to enable scholars achieving robust findings and evidence.Therefore,given the above-mentioned shortcomings,further research in the field is urgently warranted.
